Lapatinib for breast cancer: A review of the current literature

Expert Opinion on Drug Safety

Volumn 10, Issue 1, 2011, Pages 109-121

  MacFarlane, Robyn J ^a   Gelmon, Karen A ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

breast cancer; HER 2 positive; lapatinib; targeted therapy

Indexed keywords

CAPECITABINE; CARBOPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEFITINIB; GEMCITABINE; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PERTUZUMAB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRASTUZUMAB;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER RECURRENCE; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG STRUCTURE; DYSPNEA; FATIGUE; FEVER; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERCALCEMIA; INFORMATION RETRIEVAL; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MEDLINE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT RESPONSE; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 78650492709     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.533168     Document Type: Article

References (70)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
2. Cox MC, Dan TD, Swain SM, et al. Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin Emerg Drugs 2006;11:489-501
3. Slamon DG, Godolphin W. Studies of the her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12 (Pubitemid 19147683)
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplitication of the HER-2/neu oncogene. Science 1987;235:177-82
5. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7(5):e1000279
6. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92 (Pubitemid 32222155)
7. Perez E, Romond E, Suman V, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007;25(185):abstract 512
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72 (Pubitemid 41464705)
9. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84 (Pubitemid 41464706)
10. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients [abstract 52]. 29th Annual San Antonio Breast Cancer Symposium; 2006
11. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study [abstract 62]. 32nd Annual SanAntonio Breast Cancer Symposium; 2009
12. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract 1]. 28th Annual San Antonio Breast Cancer Symposium; 2005
13. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20 (Pubitemid 43290919)
14. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369(9555):29-36 (Pubitemid 46039831)
15. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15(24):7479-91
16. Ryan Q, Ibrahim A, Cohen MH, et al. FDA drug approval summary: Lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008;13:1114-19
17. Hackel PO, Zwick E, Prenzel N, et al. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999;11:184-9 (Pubitemid 29164032)
18. Lin NU, Winer EP. Small molecule tyrosine kinase inhibitors. Breast Cancer Res 2004;6:204-10
19. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55 (Pubitemid 27151960)
20. Van Cutsem E, Kan Y, Chung A, et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2) positive advanced gastric cacner (GC). J Clin Oncol 2009;27(15S):LBA astract 4509
21. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28(16):2698-704
22. Gianni L, Llado A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(7):1131-7
23. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28(7):1138-44
24. Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: Erlotinib (tarceva) tablets. Oncologist 2005;10:461-6
25. Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Semin in Rad Oncol 2005;15:245-53
26. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28(8):1301-7
27. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/EbrB-2 tyrosine kinase inhibitor, GW2016, on the growth, of human normal and tumor-derived cells lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94
28. Spector NL, Xia W, Burris H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23(11):2502-12 (Pubitemid 47050840)
29. Xia W, Mullin RJ, Keith BR, et al. Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63
30. Konecny G, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib againse HER-2 overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9 (Pubitemid 43259947)
31. Bence AK, Andersen EB, Halepota MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 2005;23:39-49
32. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmakokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23(23):5305-13
33. Burris HA, Taylor C, Jones S, et al. A phase I study of GW572016 in patients with solid tumors. Proc Am Soc Clin Oncol 2003;22(258):abstract 994
34. Moy B, Goss PE. Lapatinib associated toxicity and practical management recommendations. Oncologist 2007;12:756-65 (Pubitemid 47328219)
35. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19:1068-74 (Pubitemid 351796331)
36. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26(18):2999-3005
37. Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009;20:1026-31
38. Koch KM, Lee D, Mangum S, et al. Pharmakokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients. Eur J Cancer 2003;1(Suppl 5):559A
39. Kaufman B, Trudeau M, Awada A, et al. Lapatinib monotherapy in patients with HER-2 overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10:581-8
40. Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003;97(545):553 (Pubitemid 36125831)
41. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann Oncol 2006;17:935-44 (Pubitemid 43778983)
42. Newton HB, Slivka MA, Volpi C, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neurooncol 2006;24:5658-63 (Pubitemid 36187642)
43. Weil RJ, Palmieri DC, Bronder JL, et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;176:913-20 (Pubitemid 41416243)
44. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13:1648-55
45. Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005;23:2114-16 (Pubitemid 46211402)
46. Dawood S, Gonzalez-Angulo AM, Albarracin C, et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 2010;116(13):3084-92
47. Niwinska A, Murawska M, Lemanska I, et al. The role of systemic treatment after whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases: differences depending on biological sybtype. J Clin Oncol 2009;27(15S):abstract #1027
48. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non small cell lung cancer: a prospective trial. Ann Oncol 2004;15:1042-7 (Pubitemid 39089780)
49. Katz A, Zalewski P. Quality of life benefits and evidence of antitumor activity for patients with brain metastases treated with gefitinib. Br J Cancer 2003;89:s15-18 (Pubitemid 38068005)
50. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26(12):1993-9
51. Lin NU, Dietas V, Paul D, et al. Multicenter phase II study of lapatinib in patietns with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15(4):1452-9
52. Schwartz G, Chu QS, Hammond LA, et al. Phase I clinical, biology, and pharmacokinetic study of the combination of GW572016 and capecitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2004;23(Suppl 14):212
53. Geyer VE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43 (Pubitemid 46021510)
54. Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010;15(9):924-34
55. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capcitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-43
56. Capri G, Chang J, Chen SC, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010;21:474-80
57. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breat cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases - the UK experience. Br J Cancer 2010;102:995-1002
58. Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009;117:577-89
59. Sherrill B, Amonkar MM, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008;99:711-15
60. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, tandomized study compating lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26(34):5544-52
61. Crown JP, Burris III HA, Yardley DA, et al. Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer. J Clin Endocrinol Metab 2007;25(38S):abstract #1027
62. Finn RS, Press MF, Dering J, et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 2009;27(24):3908-15
63. Molina JR, Kaufmann SH, Reid JM, et al. Evaluation fo lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res 2008;14(23):7900-8
64. Chu QSC, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res 2008;14(14):4484-90
65. Johnston S, Pippen J, Picot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27(33):5538-46
66. Schwartzberg LS, Franco SX, Florance A, et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010;15:122-9
67. Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008;26(20):3317-23
68. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzuman-refractory metastatic breast cancer. J Clin Oncol 2010;28(7):1124-30
69. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 2009;27(12):1999-2006
70. Li X, Lewis M, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100(9):672-9